Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 pharmaceutical company AstraZeneca in Europe, has shown meaningful improvements in overall survival in people with BRCA mutated (gBCRCAm) and high-risk early breast cancer. HER2 negative, 2024 clinical trial data indicate.
Jaime Grajales Benjomia – Getty Images
